Authors
Latest:
Future of R/R MM: Emerging AgentsIn this segment, Dr Mohan asks Dr Mann about emerging investigational agents for the management of relapsed/refractory multiple myeloma (R/R MM) that show particular promise.
Latest:
Navigating High-Risk Disease in Multiple Myeloma: Treatment Strategies and the Role of ASCTExperts dive into the complexities of defining and treating high-risk Multiple Myeloma (MM) and discuss the role of ASCT in newly diagnosed MM and weigh the considerations for recommending transplants, including insights on the selection criteria for tandem transplantations.
Latest:
Guido Lancman, MD, on Next Steps for a Study of IVIG in Patients with Multiple Myeloma Receiving DaratumumabHypogammaglobulinemia was found to be nearly universal for patients with multiple myeloma during treatment with daratumumab, suggesting a role for intravenous immunoglobulin.
Latest:
Identifying Indications for Neoadjuvant Therapy in CholangiocarcinomaThe recent Hot Topics section focuses on survival rates for patients with cholangiocarcinoma.
Latest:
Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic MelanomaThis clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.
Latest:
Oncologists Reflect on Pandemic's Lasting Impact on Cancer CareHear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.
Latest:
Balancing a Family and an Emerging Career in Public HealthPublic health researchers highlight how they learned to overcome and adapt to disparities observed during their careers.
Latest:
Advanced Bladder Cancer: Future Directions in CareClosing out their panel on advanced bladder cancer management, key opinion leaders share their excitement for future evolutions within the treatment landscape.
Latest:
Use of CAR T-cell Therapy in Earlier Lines in Relapsed Refractory Multiple MyelomaPanelists discuss how the use of CAR T-cell therapy in earlier lines of treatment for relapsed/refractory multiple myeloma could potentially improve long-term outcomes, considering factors such as patient selection, optimal timing, and the impact on subsequent treatment options.
Latest:
Enfortumab Vedotin PFS May Improve Despite Specific AEs in Bladder CancerPatients with neuropathy experienced a longer PFS with enfortumab vedotin vs those without neuropathy, skin rash, or hyperglycemia.
Latest:
Sjögren Syndrome Induced by Immune Checkpoint Inhibitors in a Patient with Advanced Renal Cell CarcinomaThis clinical quandary details a Mexican man, aged 77 years, who presented to the oncology clinic with a sternal mass. Based on the results, the patient fulfilled the 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for Sjögren syndrome, thus the diagnosis triggered by immune checkpoint inhibitors was definitively established.
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Latest:
Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited SettingA recent clinical quandary focused on the diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm in a resource-limited setting.
Latest:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic CancerSuneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Latest:
Emerging Strategies to Manage Relapsed and/or Refractory Multiple MyelomaJames J. Driscoll, MD, PhD, and James Ignatz-Hoover, MD, PhD, share a perspective on a study published recently in ONCOLOGY.
Latest:
Providing Supportive Care to Patients with NSCLCHelping patients manage potential treatment-related adverse events is an essential part of the overall care plan in the treatment of non-small cell lung cancer. Experts provide strategies to address adverse events and best practices for providing the supportive care needed for patients.
Latest:
Face-Off: Award Presentations and Event ConclusionJudy concludes the event and presents the awards.
